Ticker LaunchUplisting · DCTH
Delcath Systems, Inc.
Formerly DELCATH SYSTEMS, INC.; DELCATH SYSTEMS INC
Delcath Systems, Inc. (DCTH), already reporting to the SEC, moved up to Nasdaq on May 4, 2020 with an offering at $10.00 per share raising $18.2M. Roth Capital was lead-left underwriter, joined by Aegis Capital and Laidlaw. Lowenstein Sandler advised the company and Ellenoff Grossman & Schole advised the underwriters.
Delcath Systems, Inc. is an interventional oncology company focused on primary and metastatic liver cancers. Its lead candidate, Melphalan/HDS, delivers high-dose chemotherapy to the liver while limiting systemic exposure; it is approved in Europe as CHEMOSAT and is being studied in ocular melanoma liver metastases and intrahepatic cholangiocarcinoma.
- Status
- Uplisting
- Ticker
- DCTH
- Exchange
- Nasdaq
- Listed
- May 4, 2020
- Price
- $10.00
- Raised
- $18.2M
- Market cap at IPO price
- $22.7M
- First filed
- Jun 15, 2015
- Underwriters
- Roth Capital, Aegis Capital and Laidlaw
- Company counsel
- Lowenstein Sandler
- Underwriters' counsel
- Ellenoff Grossman & Schole
- Sector
- Healthcare
- Country / state
- NY
More on this listing for subscribers
- Shares offered, over-allotment and shares outstanding after the offering
- Analyst notes on the filing
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Jun 15, 2015
- Latest amendment May 1, 2020
- Final prospectus (424B4) May 4, 2020
- All filings on EDGAR CIK 872912
Other Healthcare uplistings in 2020
- INVO Fertility, Inc.INVO · Nov 13, 2020 · $11.6M